Abstract
Introduction
Overactive Bladder Syndrome (OAB) significantly impacts quality of life, necessitating improved diagnostic tools and treatment monitoring. This study explores the potential of neurotrophins, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) as urinary biomarkers in patients with OAB undergoing mirabegron therapy, a β3-adrenergic agonist. This investigation is aimed at providing insights into the potential of neurotrophins to enhance OAB diagnosis and assess treatment efficacy.
Materials and Methods
Urinary NGF and BDNF levels were measured in 15 healthy controls and 30 patients with OAB. Patients were treated with mirabegron 50 mg once daily. Urinary NGF and BDNF levels were measured by enzyme-linked immunosorbent assay method and normalized by urinary creatinine levels (NGF/Cre and BDNF/Cre). The urinary NGF/Cre and BDNF/Cre levels were compared between controls and patients with OAB and subsequently at baseline and 3 months after mirabegron treatment. Treatment efficacy was assessed with the Indevus Urgency Severity Scale (IUSS) questionnaire.
Results
Urinary NGF/Cre and BDNF/Cre levels were significantly higher in patients with OAB than in the controls (p < 0.001 and p = 0.03 respectively). Moreover, NGF/Cre and BDNF/Cre levels significantly decreased post-mirabegron treatment (p < 0.001 and p = 0.005 respectively). Patients with improvement of OAB symptoms after treatment showed lower levels of NGF/Cre at the 3-month evaluation than those with no improvement (p = 0.05).
Conclusion
Although both NGF/Cre and BDNF/Cre levels were significantly decreased after mirabegron treatment, only NGF/Cre levels were associated with treatment response.
Similar content being viewed by others
Data Availability
The research data are available upon request.
Abbreviations
- BDNF:
-
Brain-derived neurotrophic factor
- BMI:
-
Body mass index
- Cre:
-
Creatinine
- DO:
-
Detrusor overactivity
- IUSS:
-
Indevus Urgency Severity Scale
- IQR:
-
Interquartile range
- LUTS:
-
Lower urinary tract symptoms
- NGF:
-
Nerve growth factor
- OAB:
-
Overactive bladder
- SD:
-
Standard deviation
- UTI:
-
Urinary tract infection
References
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.
Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4.
McGuire E. Bladder instability and stress incontinence. Neurourol Urodyn. 1988;7(6):563–7.
Bates CP, Bradley WE, Glen ES, et al. Third Report on the Standardisation of Terminology of Lower Urinary Tract Function: procedures related to the evaluation of micturition: pressure-flow relationships. Residual urine. Br J Urol. 1980;52(5):348–50.
Robinson D, Thiagamoorthy G, Cardozo L. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf. 2016;15(5):689–96.
Mirabegron. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed 2 September 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547887/
Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci. 2010;112(2):128–34.
Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39–45.
Ochodnicky P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol. 2012;9(11):628–37.
Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41.
Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005;174(2):604–7. https://doi.org/10.1097/01.ju.0000165461.38088.7b.
Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(Suppl 4):S7–18.
Coelho A, Oliveira R, Antunes-Lopes T, Duarte Cruz C. Partners in crime: NGF and BDNF in visceral dysfunction. Curr Neuropharmacol. 2019;17(11):1021–38. https://doi.org/10.2174/1570159X17666190617095844.
Yuk SM, Shin JH, Song KH, Na YG, Lim JS, Sul CK. Expression of brain derived-neurotrophic factor and granulocyte-colony stimulating factor in the urothelium: relation with voiding function. BMC Urol. 2015;15:37. https://doi.org/10.1186/s12894-015-0036-3
Cheng C, Li Q, Lin G, Opara EC, Zhang Y. Neurobiological insights into lower urinary tract dysfunction: evaluating the role of brain-derived neurotrophic factor. Am J Clin Exp Urol. 2023;11(6):559–77
Kashyap MP, Pore SK, de Groat WC, Chermansky CJ, Yoshimura N, Tyagi P. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Renal Physiol. 2018;315(1):F45–56.
Tsiapakidou S, Apostolidis A, Pantazis K, Grimbizis GF, Mikos T. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Int Urogynecol J. 2021;32(12):3143–55.
Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2011;107(5):799–803.
Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1)):359–65. https://doi.org/10.1016/j.juro.2012.08.187
Suh YS, Ko KJ, Kim TH, et al. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients. Int Neurourol J. 2017;21(4):270–81.
Sağır S, Bayrak Ö, Şen H, Kul S, Erturhan S, Seçkiner İ. Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection. Turk J Urol. 2021;47(3):223–8.
Birder LA, Wolf-Johnston AS, Sun Y, Chai TC. Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf). 2013;207(1):123–9.
Funding
None declared.
Author information
Authors and Affiliations
Contributions
A.B.: conceptualization, methodology, formal analysis, investigation, data curation, resources, writing—original draft preparation, visualization; A.G.: formal analysis, data curation, writing—original draft preparation, visualization; D.R.: methodology, formal analysis, resources, writing—review and editing, supervision; A.M.: methodology, formal analysis, resources; E.D.: methodology, resources, writing—review and editing, supervision; P.B.: conceptualization, methodology, investigation, resources, writing—review and editing, visualization, supervision.
Corresponding author
Ethics declarations
Conflicts of Interest
None.
Additional information
Handling Editor: G. Alessandro Digesu
Editor in Chief: Maria A. Bortolini
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Beta, A., Giannouli, A., Rizos, D. et al. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome. Int Urogynecol J (2024). https://doi.org/10.1007/s00192-024-05809-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00192-024-05809-0